OSTEOPOROSIS PRODUCTS: OPPORTUNITIES AND TRENDS IN U.S. MARKETS

139 Pages | 46 Exhibits | 2000 Analysis | Forecasts Through 2004

OVERVIEW:
Osteoporosis is the loss of bone mineral density, which contributes to weakened bone tissue and a propensity for fractures, and is one of the major contributors to orthopedic injuries, especially in women. Although the disease is not restricted to women, and many factors contribute to the cause of osteoporosis, the most significant factor for women is menopause. The population of postmenopausal women is rapidly increasing as the baby boom generation reaches middle age, and demographics is expected to increase the incidence of osteoporosis until well into the 21st century. The existing undiagnosed population and the increasing incidence of osteoporosis are creating a significant market opportunity for companies seeking to diagnose or treat the disease.

This dynamic report from Medtech Insight provides clients with primary research information obtained from more than 200 gynecologists concerning osteoporosis-screening trends, planned product/equipment purchases, osteoporosis treatment ratings, and planned use of osteoporosis treatments. This report also includes nine company profiles and market analyses of osteoporosis diagnosis and treatment products such as bone densitometry systems, biochemical markers, and anti-resorptive and bone forming drugs. In 1999, sales of osteoporosis devices and drugs totaled more than $2.5 billion.

The major topics addressed in this report from Medtech Insight include: anti-resorptive osteoporosis drugs; bone-forming osteoporosis drugs; current and planned ownership of office densitometry equipment; hospital-based and office-based bone densitometry systems; investigative osteoporosis treatments; obstacles to office-based densitometry; osteoporosis screening trends; osteoporosis treatment ratings; planned use of osteoporosis treatments; and value of densitometry and biochemical markers.

TABLE OF CONTENTS:

EXECUTIVE SUMMARY

        i. Respondent Background

        ii. Trends in Osteoporosis Diagnosis and Management

        iii. Market Analysis

 

1. TRENDS IN OSTEOPOROSIS DIAGNOSIS AND MANAGEMENT

        1.1 Osteoporosis Screening Trends

        1.2 Obstacles to Office-Based Densitometry

        1.3 Value of Densitometry and Biochemical Markers

        1.4 Current and Planned Ownership of Office Densitometry
                    Equipment

        1.5 Osteoporosis Treatment Ratings

        1.6 Planned Use of Osteoporosis Treatments

 

2. PRODUCTS AND MARKETS

        2.1 Overview of Osteoporosis

                  2.1.1 Incidence, Prevalence, and Cost

                  2.1.2 Types

                  2.1.3 Risk Factors

        2.2 Diagnosis

                  2.2.1 Bone Densitometry

                                 2.2.1.1 Indications

                                 2.2.1.2 Products by Application

                                                       2.2.1.2.1 Hospital-Based Densitometry Systems

                                                       2.2.1.2.2 Office-Based Densitometry Systems

                                                       2.2.1.2.3 Software-Based Systems

                                 2.2.1.3 Products and Suppliers

                                 2.2.1.4 Market Analyses

                  2.2.2 Biochemical Markers

                                 2.2.2.1 Types

                                 2.2.2.2 Applications

                                 2.2.2.3 Products and Suppliers

                                                       2.2.2.3.1 Ostex International

                                                       2.2.2.3.2 Metra Biosystems

                                                       2.2.2.3.3 Osteometer Biotech

                                                       2.2.2.3.4 Orion Diagnostica

                                                       2.2.2.3.5 Other Companies

                                 2.2.2.4 Market Analyses

       2.3 Treatment

                  2.3.1 Anti-Resorptive Drugs

                                 2.3.1.1 Estrogen

                                 2.3.1.2 Selective Estrogen Receptor Modulators

                                 2.3.1.3 Calcitonins

                                 2.3.1.4 Bisphosphonates

                  2.3.2 Bone Forming Drugs

                                 2.3.2.1 Sodium Fluoride

                                 2.3.2.2 Parathyroid Hormone

                  2.3.3 Other Treatments

                                 2.3.3.1 Isoflavones

                                 2.3.3.2 Osteoprotegerin

                                 2.3.3.3 Gene Therapy

                                 2.3.3.4 Statin Drugs

                                 2.3.3.5 Activators of Non-Genomic Estrogen-Like Signaling

                  2.3.4 Market Analyses

                                 2.3.4.1 Hormone Replacement Therapy Drugs

                                 2.3.4.2 Osteoporosis Drugs

                                 2.3.4.3 Share by Supplier

 

3. COMPANY PROFILES

        3.1 Hologic, Inc.

        3.2 Hybritech, Inc./Beckman Coulter, Inc.

        3.3 Eli Lilly and Company

        3.4 Lunar Corporation

        3.5 Merck & Company, Inc.

        3.6 Metra Biosystems, Inc./Quidel Corporation

        3.7 Norland Medical Systems, Inc.

        3.8 Ostex International, Inc.

        3.9 Wyeth-Ayerst Laboratories, Inc./
                  American Home Products Corporation

 

APPENDIX A

LIST OF EXHIBITS

 

Exhibit ES-1:   Osteoporosis Drugs and Devices, Market Forecast, 1998-2004  

 

Exhibit 1-1:       Average Monthly Densitometry Screening by Site, All Respondents, 1999 and 2001  

Exhibit 1-2:       Average Monthly Densitometry Screenings, by Site and Age, 1999 and 2001  

Exhibit 1-3:       Average Monthly Densitometry Screenings, by Site and Menopause Caseload, 1999 and 2001  

Exhibit 1-4:       Average Monthly Densitometry Screenings, by Site and Geographic Region, 1999 and 2001  

Exhibit 1-5:       Average Monthly Densitometry Screenings, by Site and Practice Type, 1999 and 2001  

Exhibit 1-6:       Obstacles to More Widespread Office-Based Densitometry  

Exhibit 1-7:       Existing Hormone Replacement Therapy as an Obstacle to Widespread Office Densitometry  

Exhibit 1-8:       Lack of Effective Treatment Options for Osteoporosis as an Obstacle to Widespread Office Densitometry  

Exhibit 1-9:       Credentialing Requirements as an Obstacle to Widespread Office Densitometry  

Exhibit 1-10:   Routine Screening Not Reimbursed as an Obstacle to Widespread Office Densitometry  

Exhibit 1-11:   Cost of Densitometry Equipment as an Obstacle to Widespread Office Densitometry  

Exhibit 1-12:   Lack of American College of Obstetrics and Gynecology Endorsement as an Obstacle to Widespread Office Densitometry  

Exhibit 1-13:   Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, All Respondents  

Exhibit 1-14:   Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, by Age  

Exhibit 1-15:   Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, by Menopause Caseload  

Exhibit 1-16:   Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, by Geographic Region  

Exhibit 1-17:   Acquisition Plans for Densitometry Systems Equipment  

Exhibit 1-18:   Densitometry Systems Owned and Being Purchased  

Exhibit 1-19:   Rating and Knowledge of Osteoporosis Management Approaches, All Respondents  

Exhibit 1-20:   Rating and Knowledge of Osteoporosis Management Approaches, by Age  

Exhibit 1-21:   Rating and Knowledge of Osteoporosis Management Approaches, by Menopause Caseload  

Exhibit 1-22:   Rating and Knowledge of Osteoporosis Management Approaches, by Geographic Region  

Exhibit 1-23:   Planned Use of Osteoporosis Management Approaches, All Respondents  

Exhibit 1-24:   Planned Use of Hormone Replacement Therapy, by Subcategories of Respondents  

Exhibit 1-25:   Planned Use of Selective Estrogen Receptor Modulators, by Subcategories of Respondents  

Exhibit 1-26:   Planned Use of Bisphosphonates, by Subcategories of Respondents  

Exhibit 1-27:   Planned Use of Calcitonins, by Subcategories of Respondents  

Exhibit 1-28:   Planned Use of Bone Synthesis Drugs, by Subcategories of Respondents  

 

Exhibit 2-1:       Types of Osteoporosis  

Exhibit 2-2:       Risk Factors for Primary Osteoporosis  

Exhibit 2-3:       Comparison of Bone Densitometry and Osteoporosis Biochemical Markers  

Exhibit 2-4:       Imaging Technologies Used to Diagnose Osteoporosis  

Exhibit 2-5:       1996, Clinical Comparison of Bone Measurement Techniques  

Exhibit 2-6:       1999, Selected Bone Densitometry Systems  

Exhibit 2-7:       Bone Densitometry Systems, Market Forecast, 1998-2004  

Exhibit 2-8:       1998 and 1999, Bone Densitometry Systems Market, Share by Supplier  

Exhibit 2-9:       Selected Bone Remodeling Biochemical Markers  

Exhibit 2-10:   1999, Selected Current and Emerging Bone Remodeling Biochemical Marker Tests  

Exhibit 2-11:   Bone Remodeling Biochemical Markers, Market Forecast, 1998-2004  

Exhibit 2-12:   1999, Bone Remodeling Biochemical Markers Market, Share by Supplier  

Exhibit 2-13:   1999, Selected Current and Emerging Pharmaceutical Treatments for Osteoporosis  

Exhibit 2-14:   Osteoporosis Therapy and Hormone Replacement Therapy Drugs, Market Forecast, 1998-2004  

Exhibit 2-15:   Hormone Replacement Therapy Drugs, Market Forecast, 1998-2004  

Exhibit 2-16:   Osteoporosis Therapy Drugs, Market Forecast, 1998-2004  

Exhibit 2-17:   1999, Osteoporosis Therapy and Hormone Replacement Therapy Drugs Market, Share by Supplier  



COMPANIES COVERED:

  1. Hologic, Inc.
  2. Hybritech, Inc./Beckman Coulter, Inc.
  3. Eli Lilly and Company
  4. Lunar Corporation
  5. Merck & Company, Inc.
  6. Metra Biosystems, Inc./Quidel Corporation
  7. Norland Medical Systems, Inc.
  8. Ostex International, Inc.
  9. Wyeth-Ayerst Laboratories, Inc./American Home Products Corporation
Contact Us

Need help finding medtech research? Let us help you!